Company Overview and News


Add FOLD
to your dashboard

Headline News

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-10)

Amicus Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-10 seekingalpha
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2017 Q3 earnings call. (16-0)

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics third quarter results conference call and webcast. [Operator Instructions]. As a reminder, this call is being recorded. (16-0)

Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?

2017-11-07 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Amicus Therapeutics, Inc. (FOLD - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (26-0)

An Integrated BioSci Research On Protalix - The Top BioSci Catalyst For 2018

2017-11-01 seekingalpha
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). (110-3)

Best Investment Ideas 2017

2017-10-24 seekingalpha
At the start of the year, I pressed my fellow marketplace contributors for great investment ideas. As Seeking Alpha CEO Eli Hoffman recently found out these guys are like the analysts sitting outside of Bobby Axelrod’s office and used by professional investors as their senior research team. (709-7)

Stocks of Drug Upstarts Churn Amid Wider Market’s Steady Climb - Bloomberg

2017-10-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (439-0)

Your Daily Pharma Scoop: Everybody's Gilead Problem, Halozyme's Further Progress, Ziopharm's Gene Therapy

2017-10-17 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (305-3)

Biotech Forum Daily Digest: Still Some Hope Left For Axovant Sciences?

2017-10-05 seekingalpha
The biotech sector has had a solid start to the fourth quarter as has the overall market. (382-2)

Your Daily Pharma Scoop: The First Trust NYSE Arca Biotechnology Index, Gilead's Single Pill, Acadia's New Trial

2017-10-05 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (578-4)

Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session

2017-10-05 zacks
Amicus Therapeutics, Inc. (FOLD - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 15.3% in the past one-month time frame. (26-0)

Evidence of Biotech Froth Continues to Mount - Bloomberg Gadfly

2017-10-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (86-1)

Amicus Therapeutics Wins Big at World Muscle Society Conference

2017-10-04 247wallst
Amicus Therapeutics Inc. (NASDAQ: FOLD) is another biotech player that’s seeing a nice boost from the World Muscle Society Conference in France. In this case, the company announced additional positive results from its global Phase 1/2 clinical study (ATB200-02) to investigate ATB200/AT2221 in patients with Pompe disease. (72-1)

CUSIP: 03152W109